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The purpose of this study is to correlate
the presence of TP53 gene mutations
with the clinical outcome of a cohort of
patients with diffuse large B-cell lym-
phoma (DLBCL) assembled from 12 medi-
cal centers. TP53 mutations were identi-
fied in 102 of 477 patients, and the overall
survival (OS) of patients with TP53 muta-
tions was significantly worse than those
with wild-type TP53 (P < .001). However,
subsets of TP53 mutations were found to
have different effects on OS. Mutations in
the TP53 DNA-binding domains were
the strongest predictors of poor OS
(P < .001). Mutations in the Loop-Sheet-
Helix and Loop-L3 were associated with
significantly decreased OS (P  .002), but
OS was not significantly affected by muta-
tions in Loop-L2. A subset of missense
mutations (His158, His175, Ser245,
Gln248, His273, Arg280, and Arg282) in
the DNA-binding domains had the worst
prognosis. Multivariate analysis con-
firmed that the International Prognostic
Index and mutations in the DNA-binding
domains were independent predictors of
OS. TP53 mutations also stratified pa-
tients with germinal center B cell–like
DLBCL, but not nongerminal center
B cell–like DLBCL, into molecularly dis-
tinct subsets with different survivals. This
study shows the prognostic importance
of mutations in the TP53 DNA-binding
domains in patients with DLBCL. (Blood.
2008;112:3088-3098)
Introduction
The TP53 tumor suppressor gene plays an important role in
regulation of the cell cycle, cell proliferation, apoptosis, and
genomic integrity. The p53 protein mediates cell-cycle arrest when
cells experience stressful challenges such as DNA damage, hyp-
oxia, or oncogene activation, whereas mutant p53 protein results in
cell-cycle dysregulation, genomic instability, and uncontrolled
proliferation of damaged cells.1,2 The TP53 gene also functions as
an important mediator of tumor sensitivity to radiation therapy and
chemotherapy in patients with cancer, and TP53 gene defects are
frequently seen in almost every type of human cancer.3-8
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin lymphoma and is characterized by an
aggressive clinical course.9-11 However, DLBCL exhibits consid-
erable heterogeneity in terms of clinical, morphologic, molecu-
lar, and cytogenetic features. Recent gene expression profiling
(GEP) studies have identified 3 distinct molecular subgroups of
DLBCL: germinal center B cell–like (GCB), activated B cell–
like (ABC), and primary mediastinal DLBCL.12-15 The GCB
subgroup has a germinal center molecular signature and a better
survival than does the ABC subgroup.13,16 In contrast, the
molecular signature of the ABC subgroup is similar to that of
mitogen-activated peripheral blood B cells. However, the molecu-
lar mechanisms underlying the differences in survival of the
various subgroups of DLBCL are unclear.
The presence of TP53 mutation has been correlated with a
poor response to treatment, rapid disease progression, and short
survival in several cancers. A poor prognosis was found to be
associated with specific mutations in the DNA-binding domain
of TP53 in various cancers,17-22 and recently in DLBCL.23 In
vitro studies have also shown that missense mutations in TP53
have different functional consequences and exhibit great variabil-
ity in transactivation activity, with mutations in the DNA-
binding domain usually resulting in loss of specific transactiva-
tion activity.24-26
In comparison to other cancers, the incidence of TP53 muta-
tions is much lower in the hematologic malignancies.27,28 In
DLBCL, most studies have reported that TP53 mutations are
associated with poor overall survival (OS).23,29-37 However, those
findings have not been consistent, probably reflecting the insuffi-
cient statistical power of individual studies as well as the variable
classification of the mutations.32,35 Importantly, it is unclear
whether some mutations carry a worse prognosis than others and
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whether TP53 mutations can be used as a prognostic factor to
stratify the different molecular subgroups of DLBCL.12-15 To better
understand the clinical consequences of TP53 mutations, we
assembled clinical and molecular data from a number of reported
studies to (1) correlate the structural profiles of TP53 mutations
with survival in DLBCL, (2) analyze the structural profiles of TP53
mutations in the molecular subsets of DLBCL as defined by the
GEP and immunohistochemical studies, and (3) delineate differ-
ences in the TP53 mutation profile in DLBCL compared with other
types of human cancer. Our findings show that mutations in the
TP53 DNA-binding domains are important and independent predic-
tors of survival in DLBCL.
Methods
Establishment of collaborative groups
A total of 7 groups, representing 12 medical centers in 9 countries, agreed to
participate in the study. Five groups were able to retrieve all of the
necessary clinical data,23,31,33,34,36 whereas only partial data were available
from 2 groups.29,30,32,35 The communicating authors from each group and
the number of patients contributed to the study are shown in Table 1. The
study was reviewed and approved by the Institutional Review Board at the
University of Wisconsin School of Medicine and Public Health.
Patient characteristics
This study includes a total of 477 patients with DLBCL treated with CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-
like chemotherapy with data on TP53 gene mutation status. In 329 cases, it
was possible to retrieve all or part of the clinical data, and these cases were
included in the analyses of clinicopathologic features. The clinical data
included the age, sex, Ann Arbor stage, tumor size, date of diagnosis,
performance score, sites of extranodal involvement, serum lactate dehydro-
genase (LDH) level, presence of B symptoms, International Prognostic
Index (IPI), initial chemotherapy, adjuvant radiation therapy, treatment
response, disease progression, survival, and the date of death or last
follow-up. The patients were divided into 2 groups according to TP53 gene
mutation status: mutated (21.4%) and wild type (WT; 78.6%).
TP53 mutation detection methods
Although the various TP53 mutational analyses spanned exons 2 through
11, most of the studies focused on exons 5 to 9 (Table 1). Two groups used
frozen tissue from a total of 131 specimens (27%), and 5 groups used
paraffin-embedded specimens from 346 specimens (73%). A total of
199 patients were screened by single-stranded conformation polymorphism
(SSCP) analysis followed by DNA sequencing, 103 patients were screened
by denaturing gradient gel electrophoresis (DGGE) followed by sequenc-
ing, 62 patients were screened directly by DNA sequencing, and
113 patients were screened by denaturing high-performance liquid chroma-
tography (dHPLC) followed by sequencing. The performance of each
method was validated on cell lines with known TP53 mutations before use
of the method in the study of DLBCL tumors.33,38-40 Several studies have
shown equivalent performance (90%-100% concordance) in mutation
detection accuracy between DGGE and SSCP and between DGGE and
dHPLC.38-40 No significant false-positive rate has been observed (eg,
disproportionate G-A change), and confirmatory sequencing after each
screening method would mitigate any false-positive results. The direct
sequencing method has been shown to have similar sensitivity in cases with
tumor cells constituting greater than 40% of the tissue cellularity (M.S.-B.
and M.A.P., oral communication, June 2008). The types of TP53 gene
mutation (point or frameshift) and the sites of mutation (codon, exon,
functional domain, or conserved area) were identified. For tumors with
more than one mutation, the data for each mutation was recorded as a
separate entry but analyzed as a single event for survival.
Classification of TP53 mutations for survival analysis
Mutations in exons 5 to 9 and the intervening introns were classified and
analyzed according to their location, nature, and potential effect on protein
structure and activity.41-43 Silent mutations or single nucleotide polymor-
phisms (5 cases) that did not change the amino acid sequence were not
included in the analysis. TP53 mutations were categorized in several ways
for survival analysis in comparison to the WT-TP53 group as follows:
(1) Missense mutations were defined as mutations resulting in a single
amino acid change. These included any TP53 missense mutation respon-
sible for specific structural or functional characteristics, missense mutations
affecting residues involved in direct DNA interaction (Ala119, Lys120,
Ser121, Asn239, Ser241, Met243, Asn247, Arg248, Arg273, Cys275,
Ala276, Cys277, Arg280, Arg282, and Arg283) and those at hot spot codons
(Arg175, Arg196, Arg213, Gly245, Arg248, Arg273, and Arg282).
(2) Analysis was also performed for missense mutations according to their
positions and DNA-binding domain structures in a 3-dimensional crystal
model. The DNA-binding domain included Loop-L2 (codons 164-194),
which is believed to enhance the binding affinity of TP53 with the DNA
helix under physiologic conditions; Loop-L3 (codons 237-250), which is
involved in interaction with the DNA minor groove; and the LSH motif
(Loop-Sheet-Helix; codons 119-135 and 272-287), which is involved in
DNA binding in the major groove. The survival of patients with mutations
in the DNA-binding domains was compared with patients with mutations in
non–DNA-binding domains. In addition, missense mutations affecting
residues involved in direct DNA contact (Asn239, Asn247, Arg248,
Arg273, Arg280, and Arg283) and the zinc-binding site (Cys176, His179,
Cys238, and Cys242) were evaluated by comparison to the WT-TP53
group. (3) Conserved and nonconserved missense mutations were defined
as those with a change in an amino acid residue that is conserved or not
conserved, respectively, during evolution (conservation based on CLUST-
ALW alignment of 35 p53 protein sequences from vertebrate species).
These include amino acids in highly conserved areas II (codons 117-142),
III (codons 171-181), IV (codons 234-258), and V (codons 270-286).41,42
(4) Nonmissense mutations were defined as any mutation other than a
missense mutation, including mutations introducing a stop codon, dele-
tions, or insertions (in-frame or frame-shift), and substitutions at splice
sites.5 Missense mutations were also grouped into functional classes, based
Table 1. TP53 mutation frequency in published series of diffuse large B-cell lymphoma
Collaborative groups (reference no.)
TP53-mutation
cases, n
Total cases
studied, n
Mutation
frequency, %
Methods
used
Exons
screened
Missense
mutation, %
Japan: Drs A. Ichikawa and T. Kinoshita (29) 14 64 21.9 SSCP 5-9 93
United States (NY): Dr P.R. Koduru (30) 18 84 21.4 SSCP 5-9 83
Denmark: Dr M.B. Mller (31) 7 34 20.6 DGGE 2-11 100
Spain: Drs M. Sanchez-Beato and M.A. Piris (33) 14 62 22.6 Sequencing 4-8 93
France: Drs K. Leroy, C. Haioun, and P. Gaullard (34) 16 69 23.2 DGGE 5-8 88
Brazil: Drs F.R. Kerbauy and G.W. Colleoni (36) 9 51 17.6 SSCP 5-9 100
LLMPP: Drs K.H. Young and T.C. Greiner (23) 24 113 21.2 dHPLC 5-8 83
Total 102 477 21.4 — — 91
SSCP indicates single-stranded conformation polymorphism; DGGE, denaturing gradient gel electrophoresis; LLMPP, Lymphoma and Leukemia Molecular Profiling
Project; and dHPLC, denaturing high performance liquid chromatography.
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on yeast functional assays, according to their capacity to transactivate the
promoters of several p53 target genes (WAF1, MDM2, BAX, GADD45,
p53-AIP1, and Noxa genes) using a published database.26 Three functional
groups were defined as follows: inactive, partially active, and active, with
their functionality compared with the WT-TP53 group. (5) Finally, struc-
tural classes were classified based on the effect of the mutation on the nature
of amino acid charge: polar neutral, apolar neutral, basic, and acidic, as well
as the type of amino acid change according to the lateral group.
Immunohistochemistry
Immunohistochemical studies were performed to classify DLBCL into
GCB and non-GCB types in 85 cases with the use of the following antibody
panel (CD20, CD10, MUM-1, BCL-6) and the algorithm of Hans et al.44
GEP analysis was previously described, and the results were used for
molecular classification of 113 additional cases.13,23
Statistical and survival analyses
Associations between categorical variables and TP53 mutation status were
assessed using the chi-square analysis or Fisher exact test. A nonparametric
Wilcoxon rank sum test was used to compare continuous variables between
groups. OS was defined as the time from diagnosis to death resulting from
any cause or, for patients remaining alive, the time from diagnosis to last
contact. Patients who were alive or lost in follow-up were classified as
censored observations. The Kaplan-Meier method was used for univariate
survival analysis, and the log-rank test was used to assess the difference
between survival curves. Multivariate Cox proportional hazard models
were used to evaluate which variables were independent prognostic factors
for OS.45,46 Predictive variables were selected by forward stepwise selec-
tion with a P value less than .05. The proportional hazard assumption was
verified by examining the Schoenfeld residuals. All P values are 2-sided.
Statistical analyses were performed with SAS software version 8.2 (SAS
Institute, Cary, NC).
Results
Mutation profile of the TP53 gene
The frequency and types of TP53 mutations in DLBCL are shown
in Table 1 and Figure 1. The TP53 gene was screened or sequenced
at exons 5 to 8 in 244 tumors, exons 5 to 9 in 199 tumors, and exons
2 to 11 in 34 tumors. Of the 477 cases, 102 (21.4%) had TP53
mutations, including 92 single nucleotide missense mutations and
10 other nonmissense mutations (5 single nucleotide deletions,
4 multiple nucleotide deletions, and one 10 nucleotide insertion
before Arg283). Two cases showed missense mutations with single
amino acid changes occurring in both alleles. Of these 2 cases, the
primary mutation was identified in exon 5, with the other allele
having a missense mutation in exon 6 or 7 (His193 and Ile254,
respectively). The distribution of the 102 mutations was 1 in exon
4, 33 in exon 5, 17 in exon 6, 30 in exon 7, and 21 in exon 8 (Table
1; Figure 1A). No mutations were identified in exon 9. Silent
mutations were identified in 5 cases at Ser149, Arg213, Gly244,
and Arg248.
When the TP53 mutation distribution pattern was analyzed,
68 (66%) of 102 mutations were found in codons involved in
DNA-binding motifs of the central core domain. These included
23 mutations in Loop-L3 (codons 237-250) that interacts with the
DNA minor groove, 26 mutations in the LSH helix motif (codons
119-135 and 272-287) that interacts with the DNA major groove,
and 19 mutations in Loop-L2 that enhances the binding affinity of
TP53 with the DNA helix under physiologic conditions (Figure
1B).41,42 In 37 cases, the mutations were localized to codons that
have been previously described as TP53 hot spots in non-Hodgkin
lymphoma and other cancers (Arg175, Arg196, Arg213, Gly245
Arg248, Arg273, and Arg282).47-51 Amino acid residues in the hot
spot exons were mutated at higher frequencies (2- to 10-fold) than
were other exons (Figure 1D). Ninety-two missense mutations
could be classified according to their charge and side-chain
structures, and these included 8 polar neutral, 42 apolar neutral,
20 basic, and 22 acidic mutations. In 3 cases, the mutations were
localized to codons involved in the zinc-binding site (Cys176,
His179, Cys238, and Cys242).
Mutations in 67 cases were localized to highly conserved areas
(Figure 1C): 11 mutations in area II (codons 117-142),
12 mutations in area III (codons 171-181), 28 mutations in area IV
(codons 234-258), and 16 mutations in area V (codons 270-286).
Eighty-three of the 92 missense mutations could be classified by
functionality based on the capacity to transactivate promoters of
several p53 target genes, and these included 68 inactive mutations,
9 partially active mutations, and 6 active mutations.
Correlation between TP53 mutations and clinical features
In 329 of 477 patients, clinical data were available for analysis
(292 with complete data and 37 with partial data). The patients
were treated between 1983 and 2002 and were followed for a
median of 78 months (range, 7-229 months). Of the 329 cases,
only 16 cases had a follow-up period of less than 2 years (range,
7-22 months), and these constituted only 4.9% of the analyzed
dataset. Table 2 shows the clinical and pathologic features of the
patients according to TP53 gene mutation status. The median
ages at diagnosis were 51 years (range, 13-88 years) and
64 years (range, 14-91 years) for the mutant and WT groups,
Figure 1. Schematic representation of the TP53 gene and its mutations in
diffuse large B-cell lymphoma. (A) The distribution of TP53 mutations in exons 4 to
9, (B) their relation to p53 protein structure, (C) the mutations in conserved regions,
and (D) the distribution and frequency of TP53 mutations with peaks at known hot
spot exons depicted.
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respectively. Of the 292 cases with complete clinical data, 98 cases
had a single nucleotide mutation or deletion in exons 5 to 8, one case had
a deletion in exon 4, another had an insertional mutation in exon 8, and
2 cases had mutations in introns.
TP53 mutations were significantly associated with a younger age at
diagnosis (P .003), high serum LDH level (P .001), tumor at least
10 cm (P .014), and a high IPI risk group (P .035), and these
patients were less likely to have received radiation therapy (P .004;
Table 2). Thirty-four (57%) of 60 TP53 mutated cases with treatment
response data achieved a complete remission (CR), 10 (17%) had a
partial response (PR), 6 (10%) had no response, and 10 (17%) had
progressive disease (PD) after initial chemotherapy. The patients with
mutations exhibited poorer response to this treatment than did patients
with WT-TP53 (Table 2).
Prognostic value of TP53 gene status
Patients with a TP53 mutation had a 1.9-fold increased risk of
DLBCL-specific death after treatment than did patients with
WT-TP53 in univariate analysis (Table 3). The 5 components of the
IPI and B symptoms were also found to be predictive. In
multivariate analysis, TP53 mutation and a high IPI score were
found to be independent predictors of poor survival (Table 4).
Mutation analysis also showed that patients with a TP53 mutation
in Loop-L3 and the LSH motif had hazard ratios for DLBCL-
specific death of 2.3-fold and 3.4-fold, respectively (Table 4).
Prognostic value of the DNA-binding domain mutations
Kaplan-Meier analysis showed that patients with any TP53 muta-
tion had a poor OS (median survival, 1.3 year) compared with
patients without mutation (median survival, 4.5 years; P  .001;
Figure 2A,B). Based on location, mutations in the DNA-binding
domains were the strongest predictors of poor OS (median survival,
1.0 year; P  .001; Figure 2C). In contrast, patients with mutations
in the non–DNA-binding domains had an OS similar to patients
with WT-TP53 (P  .158; Figure 2D). The 5-year OS was only
19% for patients with mutations of the DNA-binding domain
compared with 45% for patients with WT-TP53. The complete
remission rate was only 54% for patients with mutations of the
DNA-binding domain compared with 69% for patients with
WT-TP53 (Table 5).
Table 2. Clinical predictors of overall survival in patients with diffuse large B-cell lymphoma
Clinical features
All patients, n (%)
(n  292)
WT-TP53, n (%)
(n  190)
Mutated TP53, n (%)
(n  102) P*
Hazard
ratio 95% CI P†
Sex
Male 125 (51) 90 (49) 35 (55) 0.471 1.3 0.7-2.4 0.404
Female 121 (49) 92 (51) 29 (45)
Age at diagnosis
Younger than 60 y 115 (46) 76 (40) 39 (62) 0.003 0.5 0.3-0.9 0.022
At least 60 y 137 (54) 113 (60) 24 (38)
Stage
I/II 115 (46) 82 (43) 33 (52) 0.214 0.8 0.4-1.4 0.390
III/IV 137 (54) 107 (57) 30 (48)
B symptoms
No 138 (60) 109 (59) 29 (63) 0.610 0.7 0.3-1.4 0.279
Yes 93 (40) 76 (41) 17 (37)
No. of extranodal sites
Fewer than 2 211 (84) 160 (85) 51 (84) 0.844 0.8 0.3-1.7 0.490
At least 2 39 (16) 29 (15) 10 (16)
Serum LDH level
Normal 90 (40) 78 (47) 12 (20)  0.001 0.3 0.1-0.8 0.017
Elevated 135 (60) 88 (53) 47 (80)
Performance score
Low 72 (31) 58 (31) 14 (31) 0.990 1.0 0.5-2.1 0.969
High 160 (69) 129 (69) 31 (69)
Size of largest tumor
Less than 10 cm 146 (76) 110 (81) 36 (64) 0.014 0.8 0.4-1.5 0.418
At least 10 cm 46 (24) 26 (19) 20 (36)
IPI risk group
Low (0-2) 155 (66) 110 (63) 45 (78) 0.035 0.6 0.3-1.1 0.105
High (3-5) 79 (34) 66 (38) 13 (22)
Initial chemotherapy
CHOP/CHOP-like 234 (89) 161 (88) 73 (91) 0.436 1.0 0.4-2.4 0.971
Other 29 (11) 22 (12) 7 (9)
Initial radiation therapy
None 195 (74) 126 (69) 69 (86) 0.004 1.1 0.5-2.5 0.748
Involved/extended field 67 (26) 56 (31) 11 (14)
Treatment response
Complete remission 157 (66) 123 (69) 34 (57) 0.089 0.2 0.1-0.4  0.001
Partial response 37 (15) 27 (15) 10 (17)
No response 14 (6) 8 (4) 6 (10)
Progressive disease 31 (13) 21 (12) 10 (17)
LDH indicates lactate dehydrogenase; IPI, International Prognostic Index; and CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone.
*Chi-square test comparing proportions in the WT and mutated groups.
†Univariate Cox regression analysis for hazard ratio of survival.
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In Table 6, the clinical features of the patients with DNA-
binding mutations and non–DNA-binding mutations are compared.
Univariate analysis showed that the 2 groups did not differ
significantly in clinical features except that patients with DNA-
binding mutations tended to present with a larger tumor size.
Twenty-one (54%) of 41 patients with DNA-binding mutations
achieved a CR, 8 (21%) had a PR, 2 (5%) had no response, and
10 (17%) had PD after initial treatment.
When the subsets of mutations in the DNA-binding domains
were examined, patients with mutations in the Loop-L3 domain or
LSH motif had a significantly decreased OS (median survival,
1.0 year for each of the groups, P  .012 and P  .002), compared
with patients with WT-TP53 (median survival, 4.5 years; Table 7).
However, the OS was not significantly decreased for patients with
mutations in the Loop-L2 domain (Figure 3A-C; Table 7).
A total of 198 cases were classified into GCB or non-GCB
subgroups according to GEP (113 cases)13,23 or by immunohisto-
chemical stains (85 cases).44 In the GCB subgroup, mutations were
found in 24 (34%) of 71 cases, whereas 30 (24%) of 127 cases were
mutated in the non-GCB subgroup (P  .18). The TP53 mutation
profile stratified GCB-DLBCL into molecularly distinct subsets
and predicted for poor OS in those with TP53 mutations (P  .001;
Figure 4A). However, TP53 mutations did not predict for survival
in the non-GCB subgroup (Figure 4B). The predictive value of
TP53 mutations in GCB-DLBCL was mainly due to the mutations
in the DNA-binding domains (Figure 4C), but these mutations were
not predictive in the non-GCB subgroups (Figure 4D).
Prognostic values of structural subsets of TP53 mutations
Mutations in exons 5 to 9 were classified into different subsets
according to the effect or location of the mutation in the primary
sequence or tertiary structure of the p53 protein. Cases with
missense mutations as a group had a poor OS compared with the
WT-TP53 cases (P  .001; Figure 5A) but not other mutations
(nonmissense, P  .418).
The presence of TP53 mutations at direct DNA contact sites was
also associated with poor median survival and OS compared with
the WT-TP53 cases (P .004; Figure 5B). Nonfunctional inactivat-
ing mutations as defined by yeast-based assays also predicted for
poor OS compared with the WT-TP53 (P  .001; Figure 5C).
The mutations were also analyzed based on the conserved or
nonconserved status. TP53 mutations in conserved regions IV
and V, but not II and III, were associated with poor OS compared
with mutations in the nonconserved regions or WT-TP53
(P  .001; Figure 5D). The structural distribution of mutations
in these 2 regions overlapped significantly with those in the
DNA-binding domain; thus, the survival curve for these 2 re-
gions is similar to that seen for patients with the DNA-binding
domain mutations (Figure 2C).
Figure 2. Kaplan-Meier survival analysis of patients
with diffuse large B-cell lymphoma stratified by
TP53 mutation status. (A) Distribution pattern of TP53
mutations in the central core domain model designed
from published crystal structure41 (red indicates pa-
tients with poor survival; green, patients with survival
similar to WT group; blue, survival data unavailable).
(B) Overall survival of patients with TP53 mutations
versus those with WT-TP53. (C) Overall survival of
patients with DNA-binding domain mutations versus
those with WT-TP53. (D) Overall survival of patients
with non–DNA-binding domain mutations versus those
with WT-TP53.
Table 3. Univariate analysis of TP53 mutations and clinical features
in diffuse large B-cell lymphoma
Variables Hazard ratio 95% CI P
All TP53 mutations 1.9 1.3-2.8 .001
Loop-L2 mutations 1.5 0.8-2.8 .254
Loop-L3 mutations 1.8 1.0-3.2 .045
LSH domain mutations 2.0 1.2-3.6 .014
Age, 60 y 1.9 1.3-2.7  .001
Male 1.1 0.8-1.5 .764
Stage III/IV 1.8 1.3-2.6 .001
B symptoms 1.9 1.4-2.7  .001
High LDH level 2.6 1.8-3.8  .001
Tumor 10cm 1.2 0.8-1.9 .330
Extranodal sites 2 2.0 1.3-3.0 .001
High performance score 2 3.3 2.3-4.7  .001
LDH indicates lactate dehydrogenase.
Table 4. Multivariate analysis of TP53 mutations in diffuse large
B-cell lymphoma
Variables Hazard ratio 95% CI P
IPI score 3-5 2.2 1.4-3.5  .001
All TP53 mutations 1.7 1.1-2.8 .021
All TP53 DNA-binding domain mutations 3.3 2.0-5.5  .001
Loop-L2 mutations 1.6 0.7-3.3 .262
Loop-L3 mutations 2.3 1.2-4.6 .017
LSH domain mutations 3.4 1.6-7.0 .014
Direct DNA contact mutations 2.6 1.3-5.2 .007
LSH indicates loop-sheet-helix.
3092 YOUNG et al BLOOD, 15 OCTOBER 2008  VOLUME 112, NUMBER 8
For personal use only.on January 9, 2017. by guest  www.bloodjournal.orgFrom 
Approximately 36% of these TP53 mutations affect only 6
hot spot residues (His175, Ser245, Gln248, Arg249, His273, and
Arg282), and survival analysis showed that the presence of any
TP53 mutation at hot spots correlated with poor OS. These
patients had a 5-year OS of only 21% (P  .002) and a median
survival of less than 1 year. Some mutations (Tyr163 and
Arg249), which are hot spots in other cancers, were not
identified in DLBCL. A small group of missense mutants in the
DNA-binding domains (His175, Ser245, Gln248, His273,
Arg280, and Arg282) overlapped with the hot spot codons, and
they were also associated with significantly decreased survival.
The effect of these mutations was relatively homogeneous with
Table 5. Comparison of the clinical features of patients with diffuse large B-cell lymphoma with TP53 mutations in the DNA-binding domain
versus patients with WT-TP53
Clinical features WT-TP53
All TP53
mutations
DNA-binding domain
mutations
Non–DNA-binding domain
mutations
No. of cases 190 102 62 40
5-y survival (P) 45 24 (.014) 19 (.008) 32 (.412)
Median survival, y (P) 4.5 1.3 ( .001) 1.0 ( .001) 1.8 (.158)
Complete remission, % (P) 69 57 (.089) 54 (.076) 62 (.527)
Disease progression, % (P) 12 17 (.325) 21 (.143) 10 (.999)
WT indicates wild-type.
Table 6. Clinical features as predictors of overall survival in patients with diffuse large B-cell lymphoma with TP53 mutations in the DNA
and non–DNA-binding domains
Clinical features
Mutated TP53,
n (%) (n  102)
DNA-binding
domain mutations,
n (%) (n  62) HR* 95% CI P†
Non–DNA-binding
domain mutations,
n (%) (n  40) HR* 95% CI P†
Sex
Male 35 (55) 24 (57) 1.2 0.6-2.6 0.570 11 (50) 1.2 0.4-3.7 0.712
Female 29 (45) 18 (43) 11 (50)
Age at diagnosis
Younger than 60 y 39 (62) 26 (63) 0.6 0.3-1.3 0.210 13 (59) 0.4 0.1-1.1 0.084
At least 60 y 24 (38) 15 (37) 9 (41)
Stage
I/II 33 (52) 19 (46) 0.8 0.4-1.6 0.448 14 (64) 0.7 0.2-2.2 0.597
III/IV 30 (48) 22 (54) 8 (36)
B symptoms
No 29 (63) 18 (64) 1.1 0.4-2.6 0.900 11 (61) 1.1 0.3-3.6 0.901
Yes 17 (37) 10 (36) 7 (39)
No. of extranodal sites
Fewer than 2 51 (84) 35 (88) 0.5 0.2-1.4 0.174 16 (76) 1.1 0.3-4.0 0.890
At least 2 10 (16) 5 (13) 5 (24)
Serum LDH level
Normal 12 (20) 8 (21) 0.2 0.1-0.7 0.210 4 (19) 0.7 0.1-3.1 0.597
Elevated 47 (80) 30 (79) 17 (81)
Performance score
Low 14 (31) 8 (30) 0.6 0.2-1.6 0.285 6 (33) 0.7 0.2-2.3 0.507
High 31 (69) 19 (70) 12 (67)
Size of largest tumor
mass
Less than 10 cm 36 (64) 21 (60) 1.0 0.5-2.4 0.918 15 (71) 0.3 0.1-1.0 0.057
At least 10 cm 20 (36) 14 (40) 6 (29)
IPI risk group
Low (0-2) 45 (78) 30 (79) 0.3 0.1-0.9 0.026 15 (75) 0.9 0.2-3.3 0.838
High (3-5) 13 (22) 8 (21) 5 (25)
Initial chemotherapy
CHOP/CHOP-like 73 (91) 44 (90) 0.9 0.3-2.5 0.825 29 (94) 1.4 0.3-6.3 0.677
Other 7 (9) 5 (10) 2 (6)
Initial radiation therapy
None 69 (86) 41 (82) 1.7 0.7-4.4 0.271 28 (93) 0.5 0.1-2.3 0.403
Involved/extended field 11 (14) 9 (18) 2 (7)
Treatment response
Complete remission 34 (57) 21 (54) 0.2 0.1-0.5 0.001 13 (62) 0.2 0.1-0.7 0.014
Partial response 10 (17) 8 (21) 2 (10)
No response 6 (10) 2 (5) 4 (19)
Progressive disease 10 (17) 8 (21) 2 (10)
HR indicates hazard ratio; LDH, lactate dehydrogenase; IPI, International Prognostic Index; and CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone.
*Risk of diffuse large B-cell lymphoma–specific death.
†Determined by univariate Cox regression analysis for HR of survival.
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OS of less than 5 years in the majority of the patients and a
median survival of less than 1 year.
Discussion
In this study, we correlated the clinical and mutation data on
477 cases from several reported studies to investigate the prognos-
tic significance of somatic TP53 mutations in DLBCL.23,29-37 Most
studies of TP53 mutations in DLBCL have focused on exons 5 to 9,
and these exons have been shown to contain greater than 90% of
the mutations reported in different types of lymphomas.47-51 The
previous analysis of exons 2 to 11 in 34 cases in this series showed
the absence of mutations outside of exons 5 to 9, indicating that
analysis of exons 5 to 9 and their splice junctions appears adequate
in DLBCL.31
This study extends our initial observations in DLBCL23 and
confirms that the presence of TP53 mutations is an independent
predictor of OS in patients with DLBCL. The relative risk of death
from DLBCL after standard CHOP or CHOP-like chemotherapy
for patients with TP53 mutations in exons 5 to 8 was 2-fold higher
than for patients with WT-TP53. Interestingly, TP53 mutations in
the DNA-binding domains were associated with a significantly
worse OS than mutations in non–DNA-binding domains. This
finding suggests that these mutations result in loss of function,
either because of direct loss of DNA contact or because of the
conformation change that does not allow p53 to recognize its DNA
targets. Therefore, the domain location of a TP53 mutation plays a
critical role in determining the clinical outcome in DLBCL.
Biologic studies have shown that TP53 mutations are heteroge-
neous in their function; therefore, the different functions may lead
to different clinical outcomes. Functional studies of some TP53
mutants in tumor cell lines have shown loss of transcriptional
activity (p21Waf1 up-regulation) and defects in the capacity to
induce cell-cycle arrest or apoptosis.52-54 Our study shows that
mutations in the Loop-L3 and LSH motifs are the strongest
predictors of poor survival in DLBCL. Similarly, mutations
affecting the Loop-L3 and LSH motifs have been reported to
predict a poor outcome, with doxorubicin resistance, in breast and
ovarian tumors.17-22,55 Colorectal cancers with TP53 mutations in
conserved regions or affecting Loop-L3 are poorly differentiated
and more aggressive than those with other mutations.18,21 In head
and neck squamous cell carcinoma, TP53 mutations in direct DNA
contact areas resulted in accelerated tumor progression and reduced
therapeutic responsiveness.56,57 Mutations in the Loop-L2 motif do
not appear to be prognostically important in DLBCL; however, this
observation has not been reported in other human cancers.17-22 This
finding may not be representative of DLBCL because of the low
number cases with the Loop-L2 mutations in this series. Therefore,
further study is needed to evaluate the role and the predictive value
of Loop-L2 mutations in DLBCL.
Besides a loss of function of mutated p53, several studies
suggest that a gain of function of mutant p53 also confers
tumorigenetic potential by enhancing tumor cell growth or resis-
tance to drug-induced apoptosis, thereby decreasing patient sur-
vival.58-61 In DLBCL, we found that several missense mutants in
the DNA-binding domains (His158, His175, Ser245, Gln248,
His273, Arg280, and Arg282) correlated with the highest mortality
rate (median survival, 0.67 year). Blandino et al60 have shown that
particular TP53 mutants (eg, His175 and His179) may give tumor
cells a selective survival advantage during chemotherapy.60
A recent study by Song et al61 using a humanized TP53 knock-in
mouse model showed that TP53-Gln248 mice rapidly developed
certain types of cancers not commonly seen in TP53/ mice,
Table 7. Comparison of the clinical features of patients with diffuse large B-cell lymphoma with TP53 mutations in 3 DNA-binding motifs
versus patients with WT-TP53
Clinical features WT-TP53
Loop-L2
mutations
Loop-L3
mutations
LSH domain
mutations
No. of cases 190 19 23 20
5-y survival, % (P) 45 40 (.718) 19 (.087) 0 (.002)
Median survival, y (P) 4.5 1.2 (.154) 1.0 (.012) 1.0 (.002)
Complete remission, % (P) 69 54 (.222) 50 (.209) 58 (.526)
Disease progression, % (P) 12 13 (.692) 33 (.051) 17 (.641)
WT, indicates wild-type; and LSH, Loop-Sheet-Helix.
Figure 3. Prognostic significance of TP53 mutations in specific DNA-binding
motifs. (A) Overall survival of patients with mutations in the Loop-L2 domain.
(B) Overall survival of patients with mutations in the Loop-L3 motif. (C) Overall
survival of patients with mutations in the LSH domain.
3094 YOUNG et al BLOOD, 15 OCTOBER 2008  VOLUME 112, NUMBER 8
For personal use only.on January 9, 2017. by guest  www.bloodjournal.orgFrom 
indicating that some TP53 gain-of-function mutants can promote
tumorigenesis.
The gain-of-function of some TP53 mutations is also believed
to result in poor patient survival through direct or indirect effects on
the expression of genes involved in cancer progression, such as
growth regulation, metabolism, angiogenesis, drug resistance, and
genomic instability.58,59 Some TP53 mutants seen in our cases of
DLBCL (eg, His175, Trp248, His273, and Gly281) have previously
been found to activate the expression of proliferating cell nuclear
antigen62-64 and to negatively regulate CD95/Fas/Apol (a death
receptor pathway) resulting in antiapoptotic effects.65 Several
gain-of-function mutants (eg, Ala143, His175, Trp248, His273, and
Gly281) observed in our cases of DLBCL can also result in
mitogenic effects by stimulating the expression of growth factors or
growth factor receptors, such as insulin-like growth factor 1
receptor and epidermal growth factor receptor.63,66-69 In transfec-
tion assays, Ludes-Meyers et al66 found that some mutants (His175,
Trp248, His273, and Gly281) induce vascular growth factor
receptor expression and play a pivotal role during neoangiogenesis
and tumor growth. Interestingly, several mutants (His175, Trp248,
His273, and Gly281) were also found to up-regulate c-MYC in
vitro, in contrast to WT-p53, which repressed c-MYC expression.70
These mutants have also been found to induce MDR-1 gene
expression, thereby contributing to chemotherapy resistance in
tumor cell lines.62,70-72 It appears that individual TP53 mutants
share some but not all transcriptional targets and, therefore, may
result in distinct tumor phenotypes. Of particular interest, Scian et
al73 recently found that mutant p53 can increase NF-B activity and
Figure 4. Kaplan-Meier survival analysis by TP53
mutations in the molecular subtypes of diffuse
large B-cell lymphoma. (A) Overall survival of patients
with GCB-DLBCL with TP53 mutations. (B) Overall
survival of patients with non–GCB-DLBCL with TP53
mutations. (C) Overall survival of patients with GCB-
DLBCL with DNA-binding domain mutations. (D) Over-
all survival of patients with non–GCB-DLBCL with
DNA-binding domain mutations.
Figure 5. Kaplan-Meier survival analysis of patients
with diffuse large B-cell lymphoma defined by
functional or structural subsets of TP53 mutations.
(A) Overall survival of patients with missense TP53
mutations. (B) Overall survival of patients with TP53
mutations in direct DNA-contact codons. (C) Overall
survival of patients with inactivating TP53 mutations
defined by yeast functional assays. (D) Overall survival
of patients with TP53 mutations in the conserved
regions IV and V.
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protect cells against chemotherapy-induced death. A significant
correlation was also shown between the presence of endogenous
mutated p53 protein and constitutive NF-B activation in human
tumors.73 These observations suggest that particular mutations in
the DNA-binding domain can exhibit either the dominant-negative
effects or gain-of-function effects or both that are ultimately
responsible for the survival of lymphoma cells and the poor
survival of patients with DLBCL.
Another effect of some mutations (eg, His175, Gly245,
Arg248, Arg273, and Arg283) is the production of mutant p53
proteins that inhibit the tumor-suppressive activities of p63 and
p73 in vitro.74-76 These observations have also been confirmed in
mouse models showing that mutant p53 proteins (eg, His175,
Thr170, Phe270, Arg273) promote tumorigenesis through down-
regulation of p63/p73.74,75 Therefore, efforts aimed at liberating
p63/p73 from the blockade by mutant p53 might have therapeu-
tic value in cancer treatment. Future studies will be needed to
elucidate the importance of mutant TP53 on its family members,
p63 and p73, in DLBCL.
The development of DNA microarray technology has pro-
vided the opportunity for a genome-wide approach to the study
of DLBCL.12-16,77 Previously, 2 molecularly distinct subgroups
of DLBCL were identified: GCB-DLBCL and ABC-DLBCL. In
our previous study, we could not show that TP53 mutations
stratified patients prognostically within the GCB and ABC
subgroups.23 In the current series, however, we showed that the
TP53 mutations do stratify GCB-DLBCL, but not non–GCB-
DLBCL, into distinct subsets with a different OS. Therefore,
TP53 mutation and microarray analysis both contribute to the
risk stratification of patients with DLBCL. Our study strongly
indicates that identification of TP53 mutations in the DNA-
binding domains will be important for developing targeted
therapy directed at this critical tumor suppressor pathway in
patients with DLBCL.78,79
Recently, large randomized clinical trials have shown that the
addition of rituximab to standard CHOP or CHOP-like therapy has
improved the survival of patients with DLBCL.80,81 However,
preliminary studies from Farinha et al82 and our group (K.H.Y. et al,
unpublished data, August 2008) suggest that TP53 mutations will
continue to be predictive of poor OS in the rituximab-CHOP era. If
large studies confirm the adverse effect of TP53 mutations in
rituximab-CHOP–treated patients with DLBCL, novel therapeutic
strategies will be needed. Our work provides the framework to test
hypotheses about the type and location of TP53 mutations in future
studies of rituximab-CHOP–treated DLBCL.
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